DISEASES Of Interest

Comprehensive Research For Diseases of Interest

Improving quality of life by supporting the accessibility of new treatments in research trials.

Diseases of Interest

At LEADER Research, our mission is to advance the understanding and treatment of various diseases through dedicated clinical research. We focus on conditions that significantly impact patients' quality of life.

Disease of Interest

Atopic Dermatitis (Eczema)

Atopic dermatitis (eczema) is a chronic skin condition that causes patches and/or rashes that are red and itchy. It is exacerbated when the skin is dry and cracked. Atopic dermatitis is commonly associated with allergies and asthma.

Disease of Interest

Hidradenitis Suppurativa

Hidradenitis suppurativa is a chronic skin condition that results in boil-like lumps that frequently develop and leak on the areas of the body where skin rubs together, such as the armpits, groin region, and under the breasts.

Disease of Interest

Chronic Spontaneous Urticaria (Hives)

Chronic Spontaneous Urticaria (Hives) is a condition causing recurrent itchy hives and swelling without a known trigger, lasting for six weeks or more.

Disease of Interest

Chronic Inducible Urticaria (CIndU): Dermographism, Cold, And Cholinergic

Chronic Inducible Urticaria (CIndU)  includes types like dermographism, cold urticaria, and cholinergic urticaria, where hives are triggered by physical stimuli like skin pressure, cold temperatures, or heat and exercise.

Disease of Interest

Nonsegmental Vitiligo

Nonsegmental vitiligo is a skin condition characterized by the loss of pigment in patches, often symmetrically, due to the immune system attacking pigment-producing cells.

Disease of Interest

Alopecia Areata

Alopecia areata is an autoimmune condition that causes sudden, patchy hair loss on the scalp and other parts of the body. The immune system attacks hair follicles, leading to hair thinning or bald patches.

Disease of Interest

Plaque Psoriasis

Psoriasis is a chronic autoimmune skin condition that results in itchy, dry, raised skin patches (plaques) covered with gray or silver scales, commonly affecting the knees, elbows, trunk, and scalp, frequently, causing discomfort. 

Actively Recruiting Trials

CLINICAL TRIAL

RECRUITING

Atopic Dermatitis

(Eczema) Trial

Phase 2 | Injection | 16 week treatment period | 16 week safety follow up

  • ≥ 18 years old
  • Moderate to Severe Eczema, for at least 1 year
  • Eczema must cover more than 10% of the body
  • Condition must not have improved after use of creams/other treatments for at least one month

Trial ID: NCT06015308

Exclusion Criteria:

  • Received a pneumococcal vaccine, or more than two doses of the vaccine in the last 5 years
  • Received a vaccine for tetanus, diphtheria, or pertussis (whooping cough) in the last 5 years

CLINICAL TRIAL

RECRUITING

Atopic Dermatitis

(Eczema) Trial

Trial ID: NCT05995964

Phase 2 | Injection | 12 week treatment period

  • ≥ 18 years old
  • Moderate to Severe Eczema for ≥ 6 months
  • Eczema must cover more than 10% of the body
  • Condition has not improved, and have not used a topical corticosteroid or topical calcineurin inhibitor for at least one month

Exclusion Criteria:

  • Smoke more than 10 cigarettes a day
  • Heavily smoked for many years

CLINICAL TRIAL

RECRUITING

Atopic Dermatitis

(Eczema) Trial

Trial ID: NCT06241118

Phase 3 | Injection | 36 week treatment period | 16 week safety follow up

  • ≥ 12 years old
  • Moderate to Severe Eczema for at least 1 year
  • Condition has not improved after using at least one biologic Eczema medication for a minimum 4 months, or one oral JAK inhibitor for at least 2 months, or if unable to tolerate those treatments
  • Must agree to use a moisturizing cream (emollient) regularly

Exclusion Criteria:

  • Body weight under 25 kg
  • History of solid organ or stem cell transplant

CLINICAL TRIAL

Hidradenitis Suppurativa Trial

Trial ID: NCT05889182

Phase 3 | Oral tablet | 104 week treatment period | 30 day safety follow up

RECRUITING

  • ≥ 12 years old
  • Moderate to Severe Hidradenitis Suppurativa for ≥ 6 months
  • Condition has not improved after using anti-TNF treatments such as Humira or other Adalimumab biosimilars for 12 weeks, or could not tolerate treatment
  • Condition has not improved after using non-anti-TNF therapy for 16 weeks, or could not tolerate it

Exclusion Criteria:

  • Used a JAK inhibitor before, for more than 2 weeks
  • Used investigational drugs during the study

CLINICAL TRIAL

Hidradenitis Suppurativa Trial

Phase 2 | Injection | 16 week treatment period | 16 week safety follow up

Trial ID: NCT06118099

RECRUITING

  • Between 18 and 70 years old
  • Moderate to Severe Hidradenitis Suppurativa for ≥ 1 year
  • Never used biologic treatments
  • Condition has not improved after 12 weeks of oral antibiotics, or could not tolerate treatment

Exclusion Criteria:

  • Used a JAK or TYK inhibitor before
  • Used anti-OX40 or therapies targeting IL-1, IL-17, or IL-23

CLINICAL TRIAL

Hidradenitis Suppurativa Trial

Phase 3 | Oral tablet | 54 week treatment period

Trial ID: NCT06212999

RECRUITING

  • ≥ 18 years old
  • Moderate to Severe Hidradenitis Suppurativa for ≥ 3 months
  • Condition not improved after minimum 3 month systemic treatment (2-12 week washout period required prior to trial participation, if applicable)
  • Good general health

Exclusion Criteria:

  • Pregnant or breastfeeding women
  • Women who are considering pregnancy

CLINICAL TRIAL

RECRUITING

Nonsegmental Vitiligo Trial

Trial ID: NCT06113445

Phase 3 | Oral tablet | 52 week treatment period

  • ≥ 18 years old
  • Must have Vitiligo affecting both face body body with the disease affecting > 10% of the body surface area with scores of ≥ 0.5 and 5 for both face and body respectively
  • Candidate for systemic therapy
  • Good general health

Exclusion Criteria:

  • A washout period is mandatory for participants using biologics, JAK inhibitors, immunosuppressants, or undergoing phototherapy
  • Other forms of vitiligo or skin depigmentation

CLINICAL TRIAL

RECRUITING

Nonsegmental Vitiligo Trial

Trial ID: NCT06118411

Phase 3 | Oral tablet | 48-112 week treatment period

  • ≥ 12 years old and weigh ≥ 30 kg
  • Must have a history Vitiligo affecting both face and body
  • Body surface area disease affects should be between 10% and 50%
  • Actively progressing vitiligo or a history of failing ≥ 1 topical corticosteroid and/or calcineurin inhibitor treatment
  • Good general health

Exclusion Criteria:

  • Prior use of a JAK inhibitor or permanent bleaching agents
  • A washout period is mandatory for participants using biologics or undergoing phototherapy

CLINICAL TRIAL

Chronic Spontaneous Urticaria

(Hives) Trial

Phase 3b | Oral tablet | 52 week treatment period

Trial ID: NCT06042478

RECRUITING

  • ≥ 18 years old
  • Diagnosed with Chronic Spontaneous Urticaria for ≥ 6 months
  • Must have experienced the presence of itching and hives for > 6 consecutive weeks, and symptomatic within 3 months prior to the trial

Exclusion Criteria:

  • Received Remibrutinib of other BTK inhibitors
  • Received anti-IgE therapies, including Ligelizumab or Omalizumab
  • Currently on anticoagulant medication or dual anti-platelet therapy

CLINICAL TRIAL

RECRUITING

Chronis Inducible Urticaria (CIndU): Dermographism Cold, And Cholinergic Trial

Trial ID: NCT05976243

Phase 3 | Oral tablet | 52 week treatment period | 4 week safety follow up

  • ≥ 18 years old
  • Diagnosed with Dermographism, Cold Urticaria, or Cholinergic Urticaria for ≥ 4 months
  • Inadequate control of symptoms despite using H1-antihistamines (H1-AH)

Exclusion Criteria:

  • Concomitant diagnosis of Chronic Spontaneous Urticaria (Hives)
  • Received treatments using Remibrutinib or other BTK inhibitors
  • A 4 month washout period is mandatory for participants who received treatment using other  biologics
  • Using anticoagulant or anti-platelet medications, except for low doses of acetylsalicylic acid or clopidogrel

CLINICAL TRIAL

RECRUITING

Alopecia Areata

Trial

Trial ID: NCT06444451

Phase 2 | Injection | 36 week treatment period | 16 week safety follow up

  • ≥ 18 years old
  • Moderate to Severe Alopecia Areata (≥ 50% hair loss on head with a diagnosis duration of ≥ 6 months)
  • Current episode of  hair loss is less than 8 years in duration
  • No evidence of terminal hair regrowth within the past 6 months

Exclusion Criteria:

  • Other forms of alopecia or any disease that requires topical treatment on the scalp
  • Prior use of anti-OX40 therapies, Non-B-cell selective lymphocyte-depleting agents (e.g. alefacept, alemtuzumab), or JAK inhibitors for 12 months or longer

CLINICAL TRIAL

Atopic Dermatitis

(Eczema) Trial

Phase 3 | Injection | 52 week treatment period

Trial ID: NCT06224192

RECRUITING

  • ≥ 12 years old
  • Moderate to Severe Eczema with a history of the condition of ≥ 12 months
  • Must have had an inadequate response, intolerance, or contraindication to a topical corticosteroid applied for > 1 month

Exclusion Criteria:

  • Previous exposure to anti-OC40/40L therapies
  • A washout period is required for those previously treated with biologics or JAK inhibitors

CLINICAL TRIAL

RECRUITING

Hidradenitis Suppurativa Trial

Trial ID: NCT06468228

Phase 3 | Injection | 16-62 week treatment period

  • ≥ 16 years old
  • Moderate to Severe history of Hidradenitis Suppurativa with a diagnosis of ≥ 6 months
  • Inadequate response to at least 12 weeks of oral antibiotics or intolerance to such treatment

Exclusion Criteria:

  • A washout period is mandatory for participants who received treatment using other  biologic therapies

CLINICAL TRIAL

RECRUITING

Plaque Psoriasis

Trial

Trial ID: NCT06108544

Phase 3 | Oral tablet | 60 week treatment period | 4 week safety follow up

  • ≥ 18 years old
  • Moderate to Severe Plaque Psoriasis for ≥ 6 months)
  • Candidate for phototherapy or systemic treatment
  • Plaque Psoriasis must involve more than 10% of body surface area
  • Willing to discontinue current topical and/or systemic therapies, as well as anti-rheumatic drugs

Exclusion Criteria:

  • A washout period of 2-6 months may be required for participants previously treated with other biologic drugs

CLINICAL TRIAL

Alopecia Areata

Trial

Phase 3 | Oral tablet | 160 week treatment period | 30 day safety follow up

Trial ID: NCT06012240

RECRUITING

  • Between 12 and 64 years old
  • Severe Alopecia Areata  (≥ 50% hair loss on head with no significant hair regrowth with past 3 months)
  • Current episode of  hair loss is less than 8 years in duration
  • No evidence of terminal hair regrowth within the past 6 months

Exclusion Criteria:

  • Other forms of alopecia or any disease that requires topical treatment on the scalp
  • Inadequate response to previous anti-JAK therapies
  • A washout period is required for participants previously treated with biologic therapies, anti-JAKs, or other systemic treatments

Currently Not Recruiting

CLINICAL TRIAL

CLOSED

Atopic Dermatitis

(Eczema) Trial

Phase 3 | Injection | 52 week treatment period

Trial ID: NCT05633355

CLINICAL TRIAL

CLOSED

Atopic Dermatitis

(Eczema) Trial

Trial ID: NCT05398445

Phase 3 | Injection | 24 week treatment period

CLINICAL TRIAL

CLOSED

Plaque Psoriasis

Trial

Trial ID: NCT03982394

Phase 1 | Injection | 156 week treatment period

Trials Coming Soon (placeholder)

CLINICAL TRIAL

UPCOMING

Disease Of Interest

Trial

Phase X | Injection | XX week treatment period | XX week safety follow up

  • Lorem ipsum dolor sit amet, consectetur adipiscing elit
  • Lorem ipsum dolor sit amet, consectetur adipiscing elit
  • Lorem ipsum dolor sit amet, consectetur adipiscing elit
  • Lorem ipsum dolor sit amet, consectetur adipiscing elit

Trial ID: XXXXXXXXXXX

Exclusion Criteria:

  • Lorem ipsum dolor sit amet, consectetur adipiscing elit
  • Lorem ipsum dolor sit amet, consectetur adipiscing elit

CLINICAL TRIAL

UPCOMING

Disease Of Interest

Trial

Trial ID: XXXXXXXXXXX

Phase X | Injection | XX week treatment period | XX week safety follow up

  • Lorem ipsum dolor sit amet, consectetur adipiscing elit
  • Lorem ipsum dolor sit amet, consectetur adipiscing elit
  • Lorem ipsum dolor sit amet, consectetur adipiscing elit
  • Lorem ipsum dolor sit amet, consectetur adipiscing elit

Exclusion Criteria:

  • Lorem ipsum dolor sit amet, consectetur adipiscing elit
  • Lorem ipsum dolor sit amet, consectetur adipiscing elit

CLINICAL TRIAL

UPCOMING

Disease Of Interest

Trial

Trial ID: XXXXXXXXXXX

Phase X | Injection | XX week treatment period | XX week safety follow up

  • Lorem ipsum dolor sit amet, consectetur adipiscing elit
  • Lorem ipsum dolor sit amet, consectetur adipiscing elit
  • Lorem ipsum dolor sit amet, consectetur adipiscing elit
  • Lorem ipsum dolor sit amet, consectetur adipiscing elit

Exclusion Criteria:

  • Lorem ipsum dolor sit amet, consectetur adipiscing elit
  • Lorem ipsum dolor sit amet, consectetur adipiscing elit